EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The Impact of Postoperative Prophylactic Medication on Long‐Term Surgical, Severe Endoscopic and Endoscopic or Radiologic Recurrence Following Primary Ileocecal Resection in Patients With Crohn's Disease

Sebastiaan Ten Bokkel Huinink iD, Michiel T J Bak iD, Evelien M J Beelen, Nicole S Erler, Mark S Silverberg, Matthieu Allez iD, Frank Hoentjen iD, Alexander G L Bodelier, Gerard Dijkstra, Marielle Romberg-Camps, Nanne K H de Boer, Laurents P S Stassen und 6 weitere

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.18496 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Sebastiaan Ten Bokkel Huinink und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Crohn Disease, Ileum, Cecum. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The impact of prophylactic medication following ileocecal resection (ICR) for Crohn's disease (CD) merits further elucidation. Prophylactic medication following ileocecal resection (ICR) is recommended in patients with Crohn’s disease (CD), particularly in patients at increased risk of recurrence, but the impact on long‐term outcomes needs to be further elucidated.

Aim

To evaluate the effect of postoperative prophylactic medication on long‐term prognosis.

Methods

A retrospective cohort study was performed in patients with CD who underwent primary ICR between 2000‐2020 in the Netherlands. Patients were divided into two groups: postoperative prophylactic medication [< 12 weeks following ICR] versus no postoperative prophylactic medication. Outcomes were surgical recurrence [re‐resection for CD], severe endoscopic recurrence [modified Rutgeerts score (mRS) ≥ i3] and endoscopic or radiologic recurrence [mRS ≥ i2b or radiologic recurrence]. Inverse probability of treatment weighting [IPTW] method was used to adjust for confounding and selection bias. Survival and association between postoperative prophylactic medication and outcomes were assessed with Kaplan‐Meier analyses and Cox proportional hazard models.

Results

807 patients underwent ICR (median follow‐up 5.0 years); 36% received postoperative prophylactic medication. Surgical, severe endoscopic and endoscopic or radiologic recurrence rates were significantly lower in those who received prophylactic medication ( p = 0.01; p < 0.01; p < 0.01). IPTW analysis showed a lower risk of severe endoscopic and endoscopic or radiologic recurrence in patients treated with postoperative prophylactic medication (aOR 0.64; 95% CI 0.43–0.97; aOR 0.65; 95% CI 0.47–0.91), which also was identified as a protective factor for severe endoscopic (aHR 0.5; 95% CI 0.4–0.6) and endoscopic or radiologic recurrence (aHR 0.6, 95% CI 0.5–0.7) in multivariable analysis after correction for confounding factors. A comparable protective effect of postoperative prophylactic medication was sustained in patients who underwent ileocolonoscopy

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseIleumCecumHumansMaleFemaleRetrospective StudiesAdultRecurrenceMiddle AgedYoung AdultNetherlandsAdolescentPostoperative CareTreatment Outcome

Stichwörter der Autor:innen

Crohn's diseaseintestinal surgerypostoperative recurrenceprophylactic medication

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Department of Biostatistics, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Division of Gastroenterology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Gastroenterology Department, Hôpital Saint-Louis-APHP, Université Paris Cité, Paris, France.
  • Department of Gastroenterology and Hepatology, Radboud Medical Center, Nijmegen, the Netherlands.

ORCID-Profile: Sebastiaan Ten Bokkel Huinink, Michiel T J Bak, Matthieu Allez, Frank Hoentjen

Zitieren

APA

Ten Bokkel Huinink, S., Bak, M. T. J., Beelen, E. M. J., Erler, N. S., Silverberg, M. S., Allez, M., Hoentjen, F., Bodelier, A. G. L., Dijkstra, G., Romberg-Camps, M., de Boer, N. K. H., Stassen, L. P. S., van der Meulen-de Jong, A. E., West, R. L., van der Woude, C. J., van Ruler, O., de Vries, A. C., & Dutch Initiative on Crohn and Colitis (ICC) (2025). The Impact of Postoperative Prophylactic Medication on Long‐Term Surgical, Severe Endoscopic and Endoscopic or Radiologic Recurrence Following Primary Ileocecal Resection in Patients With Crohn's Disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18496

Vancouver

Ten Bokkel Huinink S, Bak MTJ, Beelen EMJ, Erler NS, Silverberg MS, Allez M, et al. The Impact of Postoperative Prophylactic Medication on Long‐Term Surgical, Severe Endoscopic and Endoscopic or Radiologic Recurrence Following Primary Ileocecal Resection in Patients With Crohn's Disease. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18496

BibTeX
@article{TenBokkelHuinink2025,
  author = {Ten Bokkel Huinink, Sebastiaan and Bak, Michiel T J and Beelen, Evelien M J and Erler, Nicole S and Silverberg, Mark S and Allez, Matthieu and Hoentjen, Frank and Bodelier, Alexander G L and Dijkstra, Gerard and Romberg-Camps, Marielle and de Boer, Nanne K H and Stassen, Laurents P S and van der Meulen-de Jong, Andrea E and West, Rachel L and van der Woude, C Janneke and van Ruler, Oddeke and de Vries, Annemarie C and Dutch Initiative on Crohn and Colitis (ICC), Dutch Initiative on Crohn and Colitis (ICC)},
  title = {The Impact of Postoperative Prophylactic Medication on Long‐Term Surgical, Severe Endoscopic and Endoscopic or Radiologic Recurrence Following Primary Ileocecal Resection in Patients With Crohn's Disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.18496}
}
Kostenlos starten →